H.C. Wainwright lowered the firm’s price target on Outlook Therapeutics (OTLK) to 50c from $1 and keeps a Neutral rating on the shares after the company received another complete response letter for ONS-5010. “This is not the first time that the company has misread FDA’s feedback and what the Agency needed to approve ONS-5010,” the analyst tells investors in a research note. H.C. Wainwright is not even sure there’s much of a commercial opportunity for ONS-5010 anymore. It is concerned about the company’s path forward.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Morning Movers: Baidu jumps following proposed spinoff of Kunlunxin
- FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA
- Why is Outlook Therapeutics (OTLK) Stock Down 61% in Pre-Market Trading?
- FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form
- Outlook Therapeutics Inc trading resumes